Observable and Investigation Model Project

Page tree

Versions Compared

Old Version 3

changes.mady.by.user Daniel Karlsson

Saved on

compared with

New Version Current

changes.mady.by.user Suzanne Santamaria

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Date

2018-04-23 20.00 UTC

Zoom Details

https://snomed.zoom.us/j/992630241

Attendees

Apologies


Objectives

  • Discuss Free(Unbound) and Total substances
  • Resolve Likelihood observables
  • Resolve Susceptibility issue

Discussion items


ItemDescriptionOwnerNotesAction 
1Welcome & apologies
Daniel Karlsson


 

 
2Conflicts of interest
Daniel Karlsson
  • None stated

  
3Previous minutes

Daniel Karlsson




4Free and Total Substances

Daniel Karlsson

Toni Morrison



4LOINC collaboration

Farzaneh Ashrafi

Daniel Karlsson

Rob Hausam

+all

  • Likelihood

    • Two distinct cases were identified:

      1. Specifying certainty (or uncertainty) about the result of an observation. Examples: Fetal sex, Trisomy 21 present by "Dosage of chromosome specific cf DNA" method.
      2. Prediction of a possible future event based on varying amount of information about the patient, from population-only based assessment (i.e. prevalence) to assessment based on several variables. Examples include 1p36 deletion risk based on population risk, Trisomy 21 risk based on maternal age, to the CHADS-VASC instrument.

Example values:

 
5Susceptibility

Farzaneh Ashrafi

  • Mapping of LOINC component for Susceptibility LOINC terms
    • Two alternatives for representing LOINC component / SNOMED Towards:
      1. Use substances: have to add combined substances for combined antibiotics, e.g. Amoxicillin+Clavulanic acid. Cannot represent strenghts. Cannot represent only vs. contains semantics(?).
      2. Use products: Depending on drug project, may represent only/contains, can represent strength, can represent combinations. This was the alternative proposed by the project group.
    • Strength-specified antibiotics are used in some susceptibility tests, particularly for mycobacteria, and the model would need to represent strengths somehow.

7Next meeting
Daniel Karlsson
  • Next meeting is on the face-to-face on 2018-04-10


 
8AOB
Daniel Karlsson
   


Meeting Files

Attachments

Recording


Previous Meetings

Content Report Table
maxResults12
showCommentsCounttrue
spacesOBSERVABLE
labelsmeeting-agenda

More Zoom details

Topic: Observables meeting

Time: this is a recurring meeting Meet anytime

Join from PC, Mac, Linux, iOS or Android:
https://snomed.zoom.us/j/992630241

Or Telephone:
Dial:
+46 (0) 8 4468 2488 (SE Toll)
+61 (0) 2 8015 2088 (AU Toll)
+32 (0) 2 588 4188 (BE Toll)
+1 647 558 0588 (CA Toll)
+56 41 256 0288 (CL Toll)
+420 2 2888 2388 (CZ Toll)
+45 89 88 37 88 (DK Toll)
+372 880 1188 (EE Toll)
+852 5808 6088 (HK Toll)
+353 (0) 1 691 7488 (IE Toll)
+972 (0) 3 978 6688 (IL Toll)
+370 5214 1488 (LT Toll)
+60 3 9212 1727 (MY Toll)
+356 2778 1288 (MT Toll)
+31 (0) 20 241 0288 (NL Toll)
+64 (0) 9 801 1188 (NZ Toll)
+64 (0) 4 831 8959 (NZ Toll)
+47 2396 0588 (NO Toll)
+48 22 307 3488 (PL Toll)
+351 308 804 188 (PT Toll)
+65 3158 7288 (SG Toll)
+421 233 056 888 (SK Toll)
+386 1888 8788 (SI Toll)
+34 91 198 0188 (ES Toll)
+41 (0) 31 528 0988 (CH Toll)
+44 (0) 20 3695 0088 (GB Toll)
+1 408 638 0968 (US Toll)
+1 646 876 9923 (US Toll)
+1 669 900 6833 (US Toll)

Meeting ID: 992 630 241

International numbers available: https://snomed.zoom.us/zoomconference?m=AQWV2VqAIGYWMcMapl9CoYjsaj1TVS7K